Meinox

Meinox Pharma is a German biotechnology company focused on developing a novel class of small molecule MEK inhibitors specifically designed for the treatment of chronic inflammatory diseases. A spin-off from the Hannover Medical School (MHH), the company targets the MAPK/ERK signaling pathway to modulate the production of pro-inflammatory cytokines. Unlike traditional MEK inhibitors used in oncology, Meinox's lead candidates are engineered for high selectivity and an improved safety profile suitable for long-term administration. The company's primary focus areas include rheumatoid arthritis, inflammatory bowel disease, and psoriasis. By leveraging its proprietary drug discovery platform, Meinox aims to address the significant unmet medical need for safer and more effective anti-inflammatory therapies.